NAPOLI, a portfolio company of the RVC Seed Fund, has plans to bring to market in 2016 the second generation of its unique biodegradable wound bandage called ‘ChitoPran’. Like its first generation, the new bandage is made of the nanofibers of chitosan, but it also contains active medicinal substances.
NAPOLI is said to complete works on addition to the bandage of trypsin enzyme that is believed to be able to effectively clean wounds. The new technology has given surgeons a unique biodegradable "bandage-scalpel" to fluidify necroses and prevent scarring; the new material is said to be replaced by the natural tissue in the human body as it is dissolved.
The NAPOLI solution is unrivalled globally, RVC claims. The bandage disappears and requires no removal after the wound is healed, which helps protect a patient from pain and the wound from further irritation. ChitoPran is believed to not only treat wounds, but to also save doctors time and overall expenses of hospitals.
The hi-tech bandage is said to positively impact all aspects of wound healing: It encourages and accelerates regeneration processes, alleviates pain, and help prevent scarring. Special formulas and technology of nanofibrous layer generation provide for unique qualities of material to speed up healing process.
Nanofibers create preconditions for excellent air permeability and moisture evaporation, providing the safest and comfortable wound treatment, and chitosan activates natural protective and recovery mechanisms in the skin cells. Due to these qualities HitoPran allows to quickly restore health after wounds of various origins: burns, decubitus, trophic ulcers, household grazes, donor sites — and is irreplaceable at treatment of mature patients: terms of recovering are reduced by 1.5 - 2 times in comparison with traditional methods of treatment.
NAPOLI has submitted to the Federal Service for the Supervision of Public Health and Social Development an application for registration of ChitoPran second generation bandage with active medicinal substances: ciprofloxacin and trypsin. An important advantage of ChitoPran second generation bandages is a considerable (at least by times) decrease in a consumption of medicinal substances due to their high bioavailability.
Currently, ChitoPran wound bandages are available in more than 40 largest drugstores of Moscow, St. Petersburg, Krasnoyarsk, Rostov-on-Don, the Crimea, and is also used by the burn centres, hospitals and polyclinics in Russia including but not limited to the following: the Scientific Research Neurosurgery Institute named after Burdenko N.N., the A.V. Vishnevsky Institute of Surgery, the Sevastopol municipal hospital No.1 named after Pirogov N.I., and others.
In 2016, NAPOLI is planning to bring its products to the international market. At the end of March 2016, the company will be awarded a CE certificate which would make it possible for the company to sell its products to the European Union (EU) and the countries accepting the EU norms.
NAPOLI was established in April 2014 by Ivan Afanasov, a graduate of the Moscow State University majoring in chemistry. His team had a ready solution in its portfolio, and in the same year it raised 2 million rubles in investment from the RVC Seed Fund and Biotechfarm. It took the team less than 3 years to move its innovation product from a lab idea to a market-ready product.
OOO (LLC) NAPOLI develops, manufactures and sells innovative coverings for treatment of wounds of various origin. The company was founded in 2014. The philosophy of Napoli — is to ensure trend-setting approach to wounds treatment. The unique biodegradable wound bandage ChitoPran developed by the company based on nanofibre encourages and accelerates regeneration processes, alleviates pain, provides healing without scarring. NAPOLI implement the entire cycle of production of ChitoPran bandages in the territory of the Russian Federation. Technologies and formulas of forming solutions are protected by patents of the Russian Federation.
About RVC Seed Fund
RVC Seed Fund, Limited Liability Company (RVC Seed Fund), was established on October 22, 2009 in implementation of the Basic Provisions of RVC OJSC Strategy. The Fund includes OJSC RVC (99.9%) and the Foundation for Assistance to Small Innovative Enterprises in Science and Technology (0.1%). The Fund is focused on investing in the Russian innovative companies with high growth potential in domestic and foreign innovation and technology markets. The Fund operated assets volume is RUB 2 billion;